UnitedHealth Q3 Results Beat Expectations, Full-Year EPS Guidance Raised
nashnova research
UnitedHealth Group posted Q3 adjusted EPS of $4.69, beating estimates by $0.55, and lifted full-year earnings guidance to at least $20.50 — above Wall Street consensus, forcing a re-examination of how the stock is priced.
How much did it actually earn this quarter?
Adjusted EPS came in at $4.69, topping consensus by $0.55 — a sizable upside surprise.
Revenue reached $112.7 billion, down 0.4% year-over-year but still $1.21 billion above expectations. This means → the top line barely moved, yet it still beat what the Street had modeled.
In plain terms = revenue was flat, but profit beat by a wide margin — the company squeezed more out of each dollar earned.
Is the profit real cash or just accounting?
Operating cash flow hit $5.1 billion, roughly 1.2× net income.
This means → for every dollar of reported profit, more than a dollar actually landed in the company's bank account.
In plain terms = the earnings are backed by real cash collection, not paper adjustments — a clean quality-of-earnings signal.
How much did full-year guidance go up?
The company raised 2026 full-year adjusted EPS guidance — non-GAAP EPS, which strips out one-time charges — to at least $20.50.
The prior range was $19.50–$20.00; Wall Street consensus sat at $19.87. The new floor clears both anchors in one move.
GAAP EPS guidance — the standard accounting profit including all charges — was updated to at least $19.50.
What does this mean for the stock?
The guidance raise exceeded consensus. This reflects management confidence in second-half profitability that runs ahead of what the market had priced in.
This means → if the Street believes the new guide is achievable, the current valuation may need to re-rate higher.
Put simply = Wall Street was valuing the stock on $19.87 in earnings; the company now says at least $20.50 — the gap is clear, and the share price has room to adjust upward.
市场有风险，内容仅供研究参考，不构成投资建议。